La catena delle opzioni mostra i dati chiave delle opzioni azionarie di HMC Capital a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per HMC Capital..

HMC Capital (OTC:HMCLF) Azioni, Catena delle Opzioni

HMC Capital Ltd is a property group focused on ownership, development, and management. The company's operating segment includes Real Estate which comprises of HMC Capital managed HomeCo Daily Needs REIT, HealthCo Healthcare and Wellness REIT, HMC Wholesale Healthcare Fund and the Last Mile Logistics Fund; Private Equity which includes the HMC Capital Partners Fund I, a high conviction strategic stakes fund; and Corporate properties which includes unallocated costs and Capital Solutions activities which includes short term investments undertaken relating to non-HMC managed funds. It generates maximum revenue from the Real Estate segment. The company portfolio comprises mainly retail and services centers.

HOME CONSORTIUM LTD by HOME CONSORTIUM LTD.

HMC Capital Ltd

Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) raises FY2024 sales outlook from $515.00 million-535.00 million to $520.00 million-540.00 million.

News

Guidance

Limbach Holdings Raises FY2024 Sales Guidance from $515.00M-535.00M to $520.00M-540.00M  VS Est. 519.25M

WIIM

UFCS

United Fire Group shares are trading higher after the company reported better-than-expected Q3 financial results.

BBAI

BigBear.ai shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Helios Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLIO#NYSE">HLIO</a>) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.54 by 9.26 percent. This is a 34.09 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $194.500 million which missed the analyst consensus estimate of $196.574 million by 1.06 percent. This is a 3.43 percent decrease over sales of $201.400 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

HLIO

Helios Technologies Q3 2024 Adj. EPS $0.59 Beats $0.54 Estimate, Sales $194.500M Miss $196.574M Estimate

2024 ANNUAL GUIDANCE(1)
NOG is reiterating capital expenditure and production guidance and adjusting certain line items. Production taxes are being adjusted to reflect current expectations for the remainder of the year. Natural gas realizations and oil differentials are being adjusted to reflect results experienced year-to-date. Per unit cash G&amp;A is being lowered as the Company has reduced certain external expenses and continues to benefit from increasing production volumes.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Prior Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revised Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Annual Production (Boe per day)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">120,000 - 124,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">120,000 - 124,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Annual Oil Production (Bbls per day)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73,000 - 76,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73,000 - 76,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Capital Expenditures ($ in millions)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890 - $970</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$890 - $970</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Wells Turned-in-Line ("TIL")</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">93.0 - 98.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">93.0 - 98.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Wells Spud</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73.0 - 78.0</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">73.0 - 78.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Expenses and Differentials:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production Expenses (per Boe)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.15 - $9.40</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.15 - $9.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production Taxes (as a percentage of Oil &amp; Gas Sales)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">9.0% - 9.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">8.5% - 9.0%(2)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Differential to NYMEX WTI (per Bbl)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($4.00) - ($4.85)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($4.00) - ($4.50)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average Realization as a Percentage of NYMEX Henry Hub (per Mcf)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">87.5% - 92.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">90.0% - 95.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">DD&amp;A Rate (per Boe)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$16.50 - $17.50</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$16.50 - $17.50</td>
</tr>
</tbody>
</table>
</figure>

NOG Reiterates Capital Expenditure And Production Guidance

loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.04) by 150 percent. The company reported quarterly sales of $314.598 million which beat the analyst consensus estimate of $275.995 million by 13.99 percent. This is a 18.42 percent increase over sales of $265.661 million the same period last year.

loanDepot Q3 2024 Adj. EPS $0.02 Beats $(0.04) Estimate, Sales $314.598M Beat $275.995M Estimate

SWIM

Latham Group shares are trading lower after the company reported worse-than-expected Q3 financial results and narrowed its FY24 sales guidance.

Carlyle Secured Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBD#NASDAQ">CGBD</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.48 by 2.08 percent. This is a 5.77 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $55.97 million which missed the analyst consensus estimate of $57.54 million by 2.74 percent. This is a 7.50 percent decrease over sales of $60.50 million the same period last year.

CGBD

Carlyle Secured Lending Q3 Adj $0.49 Beats $0.48 Estimate, Sales $55.97M Miss $57.54M Estimate

GMED

Globus Medical Sees FY24 Revenue $2.49B-$2.50B Vs $2.481B Est.; Adj. Diluted EPS $2.90-$3.00 Vs $2.85 Est.

Limbach Holdings shares are trading higher after the company reported better-than-expected Q3 financial results.

MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) affirms FY2024 Adj EPS guidance from $1.50-1.62 to $1.50-1.62 vs $1.49 analyst estimate..

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

MasterBrand expects FY 2024 Net sales Y/Y increase of low single digits; Adj. EBITDA: $385M-$405M; Adj. Diluted EPS: $1.50-$1.62  VS Est. 1.49

RVLV

Revolve Group shares are trading higher after the company reported better-than-expected Q3 financial results.

Northern Oil &amp; Gas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOG#NYSE">NOG</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.20 by 16.67 percent. This is a 19.08 percent decrease over earnings of $1.73 per share from the same period last year. The company reported quarterly sales of $513.54 million which missed the analyst consensus estimate of $542.84 million by 5.40 percent. This is a 0.37 percent increase over sales of $511.65 million the same period last year.

Northern Oil & Gas Q3 Adj $1.40 Beats $1.20 Estimate, Sales $513.54M Miss $542.84M Estimate

TMCI

Treace Medical Concepts shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

BigBear.ai Affirms 2024 Revenue Guidance $165M-$180M

BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $41.505 million which missed the analyst consensus estimate of $46.030 million by 9.83 percent. This is a 22.12 percent increase over sales of $33.988 million the same period last year.

BigBear.ai Hldgs Q3 2024 GAAP EPS $(0.05) Beats $(0.07) Estimate, Sales $41.505M Miss $46.030M Estimate

Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.65 by 27.69 percent. The company reported quarterly sales of $625.71 million which beat the analyst consensus estimate of $603.93 million by 3.61 percent. This is a 63.10 percent increase over sales of $383.64 million the same period last year.

Globus Medical Q3 2024 Adj EPS $0.83 Beats $0.65 Estimate, Sales $625.71M Beat $603.93M Estimate

B&G Foods shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 net sales guidance below estimates.

Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE&#x2122; (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018. Pursuant to the license agreement, Acadia is required to pay Neuren one-third of the net proceeds.
Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&amp;D programs in central nervous system and rare disease, and future business development.
The transaction is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Jefferies LLC acted as financial advisor to Acadia on this transaction.

Asset Sales

ACAD

Acadia Pharmaceuticals Enters Into An Agreement To Sell Its Rare Pediatric Disease Priority Review Voucher For $150M

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) reported quarterly earnings of $0.14 per share. The company reported quarterly sales of $37.640 million which missed the analyst consensus estimate of $42.000 million by 10.38 percent. This is a 649.35 percent increase over sales of $5.023 million the same period last year.

Comments

HMC Capital

HMC Capital (HMCLF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO